Sarepta Therapeutics (SRPT) Revenue (2010 - 2026)

Sarepta Therapeutics' Revenue history runs 15 years deep, the most recent figure standing at $730.8 million for Q1 2026.

• On a quarterly basis, Revenue rose 448.1% year-over-year to $730.8 million in Q1 2026; TTM through Mar 2026 was $2.2 billion, a 34.67% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, down 1.98% from the prior year.
• Revenue climbed to $730.8 million in Q1 2026 per SRPT's latest filing, from $442.9 million in the prior quarter.
• Across five years, Revenue topped out at $1.1 billion in Q4 2023 and bottomed at $133.3 million in Q1 2025.
• The 5-year median for Revenue is $399.4 million (2025), against an average of $446.8 million.
• Across the five-year window, Revenue surged 923.65% in 2022 and plunged 67.75% in 2025, its largest moves.
• Year by year, Revenue stood at $866.3 million in 2022, then climbed by 24.46% to $1.1 billion in 2023, then slumped by 38.93% to $658.4 million in 2024, then tumbled by 32.73% to $442.9 million in 2025, then soared by 64.99% to $730.8 million in 2026.
• Per Business Quant, the three latest SRPT Revenue figures stand at $730.8 million (Q1 2026), $442.9 million (Q4 2025), and $399.4 million (Q3 2025).